This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kereiakes, D. J. Articles by Gurbel, P. A. Search for Related Content PubMed Articles by Kereiakes, D. J. Articles by Gurbel, P. A.

Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention

Dean J. Kereiakes, MD, FACC^_*,_*, Paul A. Gurbel, MD, FACC

^_* Christ Hospital Heart and Vascular Center/the Lindner Research Center, Cincinnati, Ohio
Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland.

^_* Reprint requests and correspondence: Dr. Dean J. Kereiakes, The Lindner Research Center, 2123 Auburn Avenue, Suite 424, Cincinnati, Ohio 45219. (Email: lindner{at}fuse.net).

Pre-procedural platelet reactivity has been correlated with adverse ischemic events following percutaneous coronary intervention. Patients with high pre-percutaneous coronary intervention platelet reactivity demonstrate a differential response to standard doses of antiplatelet therapies and have higher residual post-treatment platelet reactivity. Peri-procedural platelet inhibition has been inversely correlated with the occurrence of adverse clinical outcomes, particularly myocardial infarction. Preliminary evidence supports the concept of a threshold for post-treatment platelet reactivity, and patients with less than 40% to 50% residual aggregation in response to 20-µmol/l adenosine diphosphate appear to have the best long-term clinical outcomes. Wide interindividual variability in response to either aspirin or clopidogrel has been demonstrated, and hyporesponsiveness to either agent has been associated with adverse clinical outcomes. Although the prevalence of either aspirin or clopidogrel resistance may be reduced by increasing the dose of medication, it cannot be eliminated, and interindividual variability in response persists. The advent of direct-acting antithrombin agents for peri-procedural anticoagulation coupled with novel antiplatelet therapies on the immediate horizon promise to enhance the safety and efficacy of peri-procedural adjunctive pharmacotherapy.

Abbreviations and Acronyms   ADP = adenosine diphosphate   COX = cyclooxgenase   GP = glycoprotein   MACE = major adverse cardiac events   PAR = protease-activated receptor   PCI = percutaneous coronary intervention   UFH = unfractionated heparin

This article has been cited by other articles:

				G. W. Reed and C. P. Cannon Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein. J. Am. Coll. Cardiol., December 13, 2011; 58(25): 2640 - 2641. [Full Text] [PDF]

				R. Kornowski, R. Mehran, G. Dangas, E. Nikolsky, A. Assali, B. E. Claessen, B. J. Gersh, S. C. Wong, B. Witzenbichler, G. Guagliumi, et al. Prognostic Impact of Staged Versus "One-Time" Multivessel Percutaneous Intervention in Acute Myocardial Infarction: Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial J. Am. Coll. Cardiol., August 9, 2011; 58(7): 704 - 711. [Abstract] [Full Text] [PDF]

				V. A. Ferraris, J. R. Brown, G. J. Despotis, J. W. Hammon, T. B. Reece, S. P. Saha, H. K. Song, E. R. Clough, L. J. Shore-Lesserson, L. T. Goodnough, et al. 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines Ann. Thorac. Surg., March 1, 2011; 91(3): 944 - 982. [Abstract] [Full Text] [PDF]

				P. A. Gurbel, U. S. Tantry, A. R. Shuldiner, and D. J. Kereiakes Genotyping: One Piece of the Puzzle to Personalize Antiplatelet Therapy J. Am. Coll. Cardiol., July 6, 2010; 56(2): 112 - 116. [Abstract] [Full Text] [PDF]

				Y.-H. Jeong, I.-S. Kim, Y. Park, M.-K. Kang, J.-S. Koh, S.-J. Hwang, C. H. Kwak, and J.-Y. Hwang Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day: Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) Study J. Am. Coll. Cardiol. Intv., July 1, 2010; 3(7): 731 - 741. [Abstract] [Full Text] [PDF]

				P. A. Gurbel, U. S. Tantry, and A. R. Shuldiner The Worry About Clopidogrel "Nonresponsiveness": Identification and Treatment in the Post-Percutaneous Coronary Intervention Patient J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1102 - 1104. [Full Text] [PDF]

				G. Dangas, R. Mehran, G. Guagliumi, A. Caixeta, B. Witzenbichler, J. Aoki, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, et al. Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1438 - 1446. [Abstract] [Full Text] [PDF]

				D. O. Williams and J. D. Abbott What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax? Circulation, September 16, 2008; 118(12): 1219 - 1222. [Full Text] [PDF]